source
- Axiom's stem cell therapy shows zero mortality in phase-1 trial for newborn brain injuriesAxiom Biosciences reported that its mesenchymal stem cell (MSC) therapy achieved a 0% mortality rate over two years in a phase‑1 study of newborns with severe brain injuries. The nine‑patient trial…
- FDA Grants Emergency Use Authorization for Ivermectin Liquid to Prevent New World Screwworm in HorsesThe U.S. Food and Drug Administration has issued an Emergency Use Authorization for an ivermectin oral solution intended for horses, aimed at preventing infestations by New World screwworm. The au…